Suleiman A. Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Suleiman A. Khan has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
3 shared publications - Krister Wennerberg
Biotech Research and Innovation Center, University of Copenhagen, Copenhagen, Denmark
2 shared publications Muhammad Ammad-Ud-Din
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2 shared publications- Muhammad Ammad-Ud-Din
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
2 shared publications - Olli Kallioniemi
Institute for Molecular Medicine Finland-FIMM, Helsinki Institute for Life Sciences-HiLIFE, University of Helsinki, Finland
2 shared publications - Samuel Kaski
Department of Computer Science, Aalto University, Espoo, Finland
2 shared publications
Latest Publications
- 30 September 2023
- Published by Springer Nature
- p. 541-552
A Generalized Deep Learning Model for Multi-disease Chest X-Ray Diagnostics
- 30 September 2023
- Published by Springer Nature
- p. 541-552
A Generalized Deep Learning Model for Multi-disease Chest X-Ray Diagnostics
- Open Access
- 21 October 2020
- Published by The Royal Society in Royal Society Open Science
- Vol. 7 (10)
An integrative machine learning approach to discovering multi-level molecular mechanisms of obesity using data from monozygotic twin pairs
We combined clinical, cytokine, genomic, methylation and dietary data from 43 young adult monozygotic twin pairs (aged 22–36 years, 53% female), where 25 of the twin pairs were substantially weight discordant (delta body mass index > 3 kg m −2 ). These measurements were originally taken as part of the TwinFat study, a substudy of The Finnish Twin Cohort study. These five large multivariate datasets (comprising 42, 71, 1587, 1605 and 63 variables, respectively) were jointly analysed using an integrative machine learning method called group factor analysis (GFA) to offer new hypotheses into the multi-molecular-level interactions associated with the development of obesity. New potential links between cytokines and weight gain are identified, as well as associations between dietary, inflammatory and epigenetic factors. This encouraging case study aims to enthuse the research community to boldly attempt new machine learning approaches which have the potential to yield novel and unintuitive hypotheses. The source code of the GFA method is publically available as the R package GFA.
- 21 October 2020
- Published by The Royal Society in Royal Society Open Science
- Vol. 7 (10)
Open AccessAn integrative machine learning approach to discovering multi-level molecular mechanisms of obesity using data from monozygotic twin pairs
We combined clinical, cytokine, genomic, methylation and dietary data from 43 young adult monozygotic twin pairs (aged 22–36 years, 53% female), where 25 of the twin pairs were substantially weight discordant (delta body mass index > 3 kg m −2 ). These measurements were originally taken as part of the TwinFat study, a substudy of The Finnish Twin Cohort study. These five large multivariate datasets (comprising 42, 71, 1587, 1605 and 63 variables, respectively) were jointly analysed using an integrative machine learning method called group factor analysis (GFA) to offer new hypotheses into the multi-molecular-level interactions associated with the development of obesity. New potential links between cytokines and weight gain are identified, as well as associations between dietary, inflammatory and epigenetic factors. This encouraging case study aims to enthuse the research community to boldly attempt new machine learning approaches which have the potential to yield novel and unintuitive hypotheses. The source code of the GFA method is publically available as the R package GFA.
- 21 May 2019
- Published by Springer Nature
- p. 57-74
Matrix and Tensor Factorization Methods for Toxicogenomic Modeling and Prediction
- 21 May 2019
- Published by Springer Nature
- p. 57-74
Matrix and Tensor Factorization Methods for Toxicogenomic Modeling and Prediction
- 1 July 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (13_Supplem) , 3883
Abstract 3883: Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia
Introduction: Ex vivo drug sensitivity studies of samples derived from acute myeloid leukemia (AML) patients have been shown to be predictive of in vivo response. These findings are based on a limited number of well-characterized agents for which in vivo patient response data and ex vivo drug sensitivity data—on that same patient—are available. To show the feasibility of scaling such ex vivo studies to large drug screens, we characterized the reproducibility of expression-based models of drug response across two independent data sets—one generated at the Oregon Health and Science University (OHSU) and the second at the Institute for Molecular Medicine Finland (FIMM). Methods: We harmonized two large-scale AML ex vivo studies screened for drug response and profiled transcriptomically—OHSU (303 AML patient samples and 160 drugs) and FIMM (48 AML samples and 480 drugs). The two panels have 94 drugs in common. Log-logistic curves were fit to the dose-response data and area under the dose-response curves (AUCs) were calculated. Predictive modeling using Ridge regression or an integrative Bayesian approach was performed for each drug AUC independently using 202 highly-variable and/or cancer-associated genes as features. Results: For each of the 94 drugs in common between the two data sets, we trained a Ridge regression model on the OHSU data set, used the model to predict response in the FIMM data set, and calculated the Pearson correlation between the predicted and observed FIMM responses. 41 of the 94 drug models had a positive and statistically significant correlation [false discovery rate (FDR) < 20%; mean ρ = 0.43; 95% CI = 0.29 – 0.77]. Drugs corresponding to the top decile of these significant models (mean ρ = 0.54; 95% CI = 0.48 – 0.77) clustered into four primary classes: MEK inhibitors (PD184352, Selumetinib, and Trametinib), EGFR/VEGFR inhibitors (Cabozantinib, Erlotinib, Foretinib, and Sorafenib), and singletons Venetoclax and Sirolimus. To confirm these results, we applied a second modeling approach—an integrative Bayesian machine learning method—that allows systematic combination of both data sets. Training and evaluation of this approach using 10-fold cross validation yielded 82 positive and statistically significant correlations (FDR < 20%; mean ρ = 0.35; 95% CI = 0.13 – 0.58). Five of nine drugs (Cabozantinib, Selumetinib, Sirolimus, Sorafenib, and Trametinib) corresponding to the top decile of these significant models (mean ρ = 0.54; 95% CI = 0.49 – 0.60) overlapped with drugs from the top decile of Ridge results (one-sided Fisher p = 2.5 x 10-4) Conclusions: Our results using independent data sets and two statistical approaches suggest that certain drugs (including MEK and EGFR/VEGFR inhibitors) are amenable to expression-based predictive modeling in AML. Future work will focus on inferring individual biomarkers of response. Citation Format: Brian S. White, Suleiman A. Khan, Muhammad Ammad-ud-din, Swapnil Potdar, Mike J. Mason, Cristina E. Tognon, Brian J. Druker, Caroline A. Heckman, Olli P. Kallioniemi, Stephen E. Kurtz, Kimmo Porkka, Jeffrey W. Tyner, Tero Aittokallio, Krister Wennerberg, Justin Guinney. Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3883.
- 1 July 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (13_Supplem) , 3883
Abstract 3883: Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia
Introduction: Ex vivo drug sensitivity studies of samples derived from acute myeloid leukemia (AML) patients have been shown to be predictive of in vivo response. These findings are based on a limited number of well-characterized agents for which in vivo patient response data and ex vivo drug sensitivity data—on that same patient—are available. To show the feasibility of scaling such ex vivo studies to large drug screens, we characterized the reproducibility of expression-based models of drug response across two independent data sets—one generated at the Oregon Health and Science University (OHSU) and the second at the Institute for Molecular Medicine Finland (FIMM). Methods: We harmonized two large-scale AML ex vivo studies screened for drug response and profiled transcriptomically—OHSU (303 AML patient samples and 160 drugs) and FIMM (48 AML samples and 480 drugs). The two panels have 94 drugs in common. Log-logistic curves were fit to the dose-response data and area under the dose-response curves (AUCs) were calculated. Predictive modeling using Ridge regression or an integrative Bayesian approach was performed for each drug AUC independently using 202 highly-variable and/or cancer-associated genes as features. Results: For each of the 94 drugs in common between the two data sets, we trained a Ridge regression model on the OHSU data set, used the model to predict response in the FIMM data set, and calculated the Pearson correlation between the predicted and observed FIMM responses. 41 of the 94 drug models had a positive and statistically significant correlation [false discovery rate (FDR) < 20%; mean ρ = 0.43; 95% CI = 0.29 – 0.77]. Drugs corresponding to the top decile of these significant models (mean ρ = 0.54; 95% CI = 0.48 – 0.77) clustered into four primary classes: MEK inhibitors (PD184352, Selumetinib, and Trametinib), EGFR/VEGFR inhibitors (Cabozantinib, Erlotinib, Foretinib, and Sorafenib), and singletons Venetoclax and Sirolimus. To confirm these results, we applied a second modeling approach—an integrative Bayesian machine learning method—that allows systematic combination of both data sets. Training and evaluation of this approach using 10-fold cross validation yielded 82 positive and statistically significant correlations (FDR < 20%; mean ρ = 0.35; 95% CI = 0.13 – 0.58). Five of nine drugs (Cabozantinib, Selumetinib, Sirolimus, Sorafenib, and Trametinib) corresponding to the top decile of these significant models (mean ρ = 0.54; 95% CI = 0.49 – 0.60) overlapped with drugs from the top decile of Ridge results (one-sided Fisher p = 2.5 x 10-4) Conclusions: Our results using independent data sets and two statistical approaches suggest that certain drugs (including MEK and EGFR/VEGFR inhibitors) are amenable to expression-based predictive modeling in AML. Future work will focus on inferring individual biomarkers of response. Citation Format: Brian S. White, Suleiman A. Khan, Muhammad Ammad-ud-din, Swapnil Potdar, Mike J. Mason, Cristina E. Tognon, Brian J. Druker, Caroline A. Heckman, Olli P. Kallioniemi, Stephen E. Kurtz, Kimmo Porkka, Jeffrey W. Tyner, Tero Aittokallio, Krister Wennerberg, Justin Guinney. Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3883.
- Open Access
tensorBF: an R package for Bayesian tensor factorization
With recent advancements in measurement technologies, many multi-way and tensor datasets have started to emerge. Exploiting the natural tensor structure in the data has been shown to be advantageous for both explorative and predictive studies in several application areas of bioinformatics and computational biology. Therefore, there has subsequently arisen a need for robust and flexible tools for effectively analyzing tensor data sets. We present the R package tensorBF, which is the first R package providing Bayesian factorization of a tensor. Our package implements a generative model that automatically identifies the number of factors needed to explain the tensor, overcoming a key limitation of traditional tensor factorizations. We also recommend best practices when using tensor factorizations for both, explorative and predictive analysis with an example application on drug response dataset. The package also implements tools related to the normalization of data, informative noise priors and visualization. Availability: The package is available at https://cran.r-project.org/package=tensorBF .
Open AccesstensorBF: an R package for Bayesian tensor factorization
With recent advancements in measurement technologies, many multi-way and tensor datasets have started to emerge. Exploiting the natural tensor structure in the data has been shown to be advantageous for both explorative and predictive studies in several application areas of bioinformatics and computational biology. Therefore, there has subsequently arisen a need for robust and flexible tools for effectively analyzing tensor data sets. We present the R package tensorBF, which is the first R package providing Bayesian factorization of a tensor. Our package implements a generative model that automatically identifies the number of factors needed to explain the tensor, overcoming a key limitation of traditional tensor factorizations. We also recommend best practices when using tensor factorizations for both, explorative and predictive analysis with an example application on drug response dataset. The package also implements tools related to the normalization of data, informative noise priors and visualization. Availability: The package is available at https://cran.r-project.org/package=tensorBF .
- 10 June 2016
- Published by Springer Nature in Machine Learning
- Vol. 105 (2) , 233-253
Bayesian multi-tensor factorization
- 10 June 2016
- Published by Springer Nature in Machine Learning
- Vol. 105 (2) , 233-253
Bayesian multi-tensor factorization
- Top Cited PapersOpen Access
- 1 June 2014
- Published by Springer Nature in Nature Biotechnology
- Vol. 32 (12) , 1202-1212
A community effort to assess and improve drug sensitivity prediction algorithms
A community of researchers report the lessons learned from applying 44 algorithms to predict drug sensitivity in cancer cell lines using genomic, epigenetic and proteomic datasets Predicting the best treatment strategy from genomic information is a core goal of precision medicine. Here we focus on predicting drug response based on a cohort of genomic, epigenomic and proteomic profiling data sets measured in human breast cancer cell lines. Through a collaborative effort between the National Cancer Institute (NCI) and the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project, we analyzed a total of 44 drug sensitivity prediction algorithms. The top-performing approaches modeled nonlinear relationships and incorporated biological pathway information. We found that gene expression microarrays consistently provided the best predictive power of the individual profiling data sets; however, performance was increased by including multiple, independent data sets. We discuss the innovations underlying the top-performing methodology, Bayesian multitask MKL, and we provide detailed descriptions of all methods. This study establishes benchmarks for drug sensitivity prediction and identifies approaches that can be leveraged for the development of new methods.
- 1 June 2014
- Published by Springer Nature in Nature Biotechnology
- Vol. 32 (12) , 1202-1212
Top Cited PapersOpen AccessA community effort to assess and improve drug sensitivity prediction algorithms
A community of researchers report the lessons learned from applying 44 algorithms to predict drug sensitivity in cancer cell lines using genomic, epigenetic and proteomic datasets Predicting the best treatment strategy from genomic information is a core goal of precision medicine. Here we focus on predicting drug response based on a cohort of genomic, epigenomic and proteomic profiling data sets measured in human breast cancer cell lines. Through a collaborative effort between the National Cancer Institute (NCI) and the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project, we analyzed a total of 44 drug sensitivity prediction algorithms. The top-performing approaches modeled nonlinear relationships and incorporated biological pathway information. We found that gene expression microarrays consistently provided the best predictive power of the individual profiling data sets; however, performance was increased by including multiple, independent data sets. We discuss the innovations underlying the top-performing methodology, Bayesian multitask MKL, and we provide detailed descriptions of all methods. This study establishes benchmarks for drug sensitivity prediction and identifies approaches that can be leveraged for the development of new methods.